{"id":698,"date":"2024-12-27T03:16:38","date_gmt":"2024-12-27T03:16:38","guid":{"rendered":"http:\/\/interrogacao.org\/?p=698"},"modified":"2024-12-27T03:16:38","modified_gmt":"2024-12-27T03:16:38","slug":"a-study-investigated-the-use-in-il-15-in-combination-therapies-and-as-an-adjuvant-in-t-or-nk-cell-therapies-31","status":"publish","type":"post","link":"https:\/\/interrogacao.org\/?p=698","title":{"rendered":"\ufeffA study investigated the use in IL-15 in combination therapies and as an adjuvant in T- or NK-cell therapies (31)"},"content":{"rendered":"

\ufeffA study investigated the use in IL-15 in combination therapies and as an adjuvant in T- or NK-cell therapies (31). Another cytokine from the IL-2 family is IL-21, which exerts poor effects on the activation of Tregs, but is considered a potent driver of NK cell activation and proliferation (7). half of the 20th century have been invaluable in the effective treatment of a number of types of tumor. However, these therapeutic approaches have largely reached their potential, and any improvement in therapeutic outcomes has to involve novel, more effective therapeutic approaches (1). In recent decades, cancer immunotherapy has emerged as a promising therapeutic approach for the effective treatment of various tumors including but not limited to breast cancer, colorectal cancer and pancreatic cancer (2,3). Intricately organized, the immune system consists of several components that are capable of recognizing and reacting to foreign pathogens, such as lymphoid organs, B and T cells and cytokines, such as interferons and colony stimulating factors (4). The cells of the immune system are widely distributed, localizing in the lymph nodes as well as other tissues and organs (4). However, the fight against cancer is complex, as cancer cells have been demonstrated to employ several mechanisms of immune tolerance. Tumors form immune-suppressive microenvironments through the presence of T regulatory cells (Tregs) or suppressive myeloid cells, allowing them to evade the immune system (5). The presence of Tregs and suppressive myeloid cells in the tumor microenvironment supports the hypothesis that the immune targeting of cancer is a viable treatment option (1,5). In addition, the number of available immunotherapy options is an advantage when it comes to cancer therapy due to the variations that occur in various tumor types. One major limitation that cancer immunotherapy presents that certain treatments, such as cancer vaccines and adoptive cell are characterized by high inter-patient variability (6). Thus, such treatment may not be considered universal, and may be effective for only a subgroup of patients. The present review discusses the following immunotherapy approaches: The use of cytokines, adoptive cell transfer, immune checkpoint inhibitors (ICIs), vaccines and monoclonal antibodies. The different subtypes of checkpoint inhibitors and vaccines have been tabulated in Tables I and ?andII,II, respectively. In addition, various immunotherapeutic approaches are evaluated, and the potential use of combination therapy is assessed. The immunotherapy drugs and techniques available in the market were summarized in Table III. Table I. Classes of immune checkpoints, their modes of action, inhibitors, types of cancer they target and the associated cardiac adverse effects (49). expanded tumor MLN-4760 infiltrating lymphocytes (TILs) with a high-dose IL-2 regimen and lymphodepletion for the treatment of patients with metastatic melanoma (17). In this approach, TILs were rapidly expanded in the presence of anti-CD3, feeder cells and IL-2, and infused into the patients, and an overall response of 50% was reported in patients with metastatic melanoma (17). Drawbacks of IL2 therapy The effective use of IL-2 in cancer treatment is hampered by several drawbacks, the main one being its short serum half-life, which is mostly due to rapid metabolism and elimination by the kidneys (18). MLN-4760<\/a> Thus, IL-2 has to be administered repeatedly (every 8 h) at high doses, which can lead to severe toxicity such as hypotension, cardiac problems and pulmonary edema (18). In addition, Krieg (18) have reported that the binding of IL-2 to high-affinity IL-2Ra-expressing endothelial MLN-4760 cells causes acute vasodilation effects that, in turn, lead to the development of vascular leak syndrome. Cytokines in combination therapy Cytokines are a diverse group of molecules, each of which can be used to target specific cells and activate unique pathways to obtain an overall therapeutic effect. Cytokines can also be combined with other therapeutic agents that work synergistically in order to provide significant advantages over monotherapy (19). Ovarian cancer is a type of cancer in which combination immunotherapy has shown promising results; one of the ATP2A2<\/a> emerging therapies for ovarian cancer is targeting its arginine auxotrophy by depriving it of arginine, using a recombinant human arginase, inducing autophagy and subsequenT cell death (19). On the other hand, combination immunotherapy has also been.<\/p>\n","protected":false},"excerpt":{"rendered":"

\ufeffA study investigated the use in IL-15 in combination therapies and as an adjuvant in T- or NK-cell therapies (31). Another cytokine from the IL-2 family is IL-21, which exerts poor effects on the activation of Tregs, but is considered a potent driver of NK cell activation and proliferation (7). half of the 20th century […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-698","post","type-post","status-publish","format-standard","hentry","category-src-kinase"],"yoast_head":"\n\ufeffA study investigated the use in IL-15 in combination therapies and as an adjuvant in T- or NK-cell therapies (31) - Current concepts in The identification and characterisation of Rho Kinase Inhibitors<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/interrogacao.org\/?p=698\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"\ufeffA study investigated the use in IL-15 in combination therapies and as an adjuvant in T- or NK-cell therapies (31) - Current concepts in The identification and characterisation of Rho Kinase Inhibitors\" \/>\n<meta property=\"og:description\" content=\"\ufeffA study investigated the use in IL-15 in combination therapies and as an adjuvant in T- or NK-cell therapies (31). Another cytokine from the IL-2 family is IL-21, which exerts poor effects on the activation of Tregs, but is considered a potent driver of NK cell activation and proliferation (7). half of the 20th century […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/interrogacao.org\/?p=698\" \/>\n<meta property=\"og:site_name\" content=\"Current concepts in The identification and characterisation of Rho Kinase Inhibitors\" \/>\n<meta property=\"article:published_time\" content=\"2024-12-27T03:16:38+00:00\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/interrogacao.org\\\/?p=698#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/interrogacao.org\\\/?p=698\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\\\/\\\/interrogacao.org\\\/#\\\/schema\\\/person\\\/9d902a39920e069aa8351f1dcc7f042c\"},\"headline\":\"\ufeffA study investigated the use in IL-15 in combination therapies and as an adjuvant in T- or NK-cell therapies (31)\",\"datePublished\":\"2024-12-27T03:16:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/interrogacao.org\\\/?p=698\"},\"wordCount\":683,\"articleSection\":[\"Src Kinase\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/interrogacao.org\\\/?p=698\",\"url\":\"https:\\\/\\\/interrogacao.org\\\/?p=698\",\"name\":\"\ufeffA study investigated the use in IL-15 in combination therapies and as an adjuvant in T- or NK-cell therapies (31) - Current concepts in The identification and characterisation of Rho Kinase Inhibitors\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/interrogacao.org\\\/#website\"},\"datePublished\":\"2024-12-27T03:16:38+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/interrogacao.org\\\/#\\\/schema\\\/person\\\/9d902a39920e069aa8351f1dcc7f042c\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/interrogacao.org\\\/?p=698#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/interrogacao.org\\\/?p=698\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/interrogacao.org\\\/?p=698#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/interrogacao.org\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"\ufeffA study investigated the use in IL-15 in combination therapies and as an adjuvant in T- or NK-cell therapies (31)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/interrogacao.org\\\/#website\",\"url\":\"https:\\\/\\\/interrogacao.org\\\/\",\"name\":\"Current concepts in The identification and characterisation of Rho Kinase Inhibitors\",\"description\":\"Just another WordPress site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/interrogacao.org\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/interrogacao.org\\\/#\\\/schema\\\/person\\\/9d902a39920e069aa8351f1dcc7f042c\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/84f70ab93180dc5fbd16f7ba36d369a0d5f4b4bfcf63033e4e5585f4ac0c1317?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/84f70ab93180dc5fbd16f7ba36d369a0d5f4b4bfcf63033e4e5585f4ac0c1317?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/84f70ab93180dc5fbd16f7ba36d369a0d5f4b4bfcf63033e4e5585f4ac0c1317?s=96&d=mm&r=g\",\"caption\":\"admin\"},\"sameAs\":[\"http:\\\/\\\/interrogacao.org\"],\"url\":\"https:\\\/\\\/interrogacao.org\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\ufeffA study investigated the use in IL-15 in combination therapies and as an adjuvant in T- or NK-cell therapies (31) - Current concepts in The identification and characterisation of Rho Kinase Inhibitors","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/interrogacao.org\/?p=698","og_locale":"en_US","og_type":"article","og_title":"\ufeffA study investigated the use in IL-15 in combination therapies and as an adjuvant in T- or NK-cell therapies (31) - Current concepts in The identification and characterisation of Rho Kinase Inhibitors","og_description":"\ufeffA study investigated the use in IL-15 in combination therapies and as an adjuvant in T- or NK-cell therapies (31). Another cytokine from the IL-2 family is IL-21, which exerts poor effects on the activation of Tregs, but is considered a potent driver of NK cell activation and proliferation (7). half of the 20th century […]","og_url":"https:\/\/interrogacao.org\/?p=698","og_site_name":"Current concepts in The identification and characterisation of Rho Kinase Inhibitors","article_published_time":"2024-12-27T03:16:38+00:00","author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/interrogacao.org\/?p=698#article","isPartOf":{"@id":"https:\/\/interrogacao.org\/?p=698"},"author":{"name":"admin","@id":"https:\/\/interrogacao.org\/#\/schema\/person\/9d902a39920e069aa8351f1dcc7f042c"},"headline":"\ufeffA study investigated the use in IL-15 in combination therapies and as an adjuvant in T- or NK-cell therapies (31)","datePublished":"2024-12-27T03:16:38+00:00","mainEntityOfPage":{"@id":"https:\/\/interrogacao.org\/?p=698"},"wordCount":683,"articleSection":["Src Kinase"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/interrogacao.org\/?p=698","url":"https:\/\/interrogacao.org\/?p=698","name":"\ufeffA study investigated the use in IL-15 in combination therapies and as an adjuvant in T- or NK-cell therapies (31) - Current concepts in The identification and characterisation of Rho Kinase Inhibitors","isPartOf":{"@id":"https:\/\/interrogacao.org\/#website"},"datePublished":"2024-12-27T03:16:38+00:00","author":{"@id":"https:\/\/interrogacao.org\/#\/schema\/person\/9d902a39920e069aa8351f1dcc7f042c"},"breadcrumb":{"@id":"https:\/\/interrogacao.org\/?p=698#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/interrogacao.org\/?p=698"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/interrogacao.org\/?p=698#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/interrogacao.org\/"},{"@type":"ListItem","position":2,"name":"\ufeffA study investigated the use in IL-15 in combination therapies and as an adjuvant in T- or NK-cell therapies (31)"}]},{"@type":"WebSite","@id":"https:\/\/interrogacao.org\/#website","url":"https:\/\/interrogacao.org\/","name":"Current concepts in The identification and characterisation of Rho Kinase Inhibitors","description":"Just another WordPress site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/interrogacao.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/interrogacao.org\/#\/schema\/person\/9d902a39920e069aa8351f1dcc7f042c","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/84f70ab93180dc5fbd16f7ba36d369a0d5f4b4bfcf63033e4e5585f4ac0c1317?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/84f70ab93180dc5fbd16f7ba36d369a0d5f4b4bfcf63033e4e5585f4ac0c1317?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/84f70ab93180dc5fbd16f7ba36d369a0d5f4b4bfcf63033e4e5585f4ac0c1317?s=96&d=mm&r=g","caption":"admin"},"sameAs":["http:\/\/interrogacao.org"],"url":"https:\/\/interrogacao.org\/?author=1"}]}},"_links":{"self":[{"href":"https:\/\/interrogacao.org\/index.php?rest_route=\/wp\/v2\/posts\/698","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/interrogacao.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/interrogacao.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/interrogacao.org\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/interrogacao.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=698"}],"version-history":[{"count":1,"href":"https:\/\/interrogacao.org\/index.php?rest_route=\/wp\/v2\/posts\/698\/revisions"}],"predecessor-version":[{"id":699,"href":"https:\/\/interrogacao.org\/index.php?rest_route=\/wp\/v2\/posts\/698\/revisions\/699"}],"wp:attachment":[{"href":"https:\/\/interrogacao.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=698"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/interrogacao.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=698"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/interrogacao.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=698"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}